Carcinoma Transitional Cell/*diagnostic imaging/*pathology Humans *Multiparametric Magnetic Resonance Imaging Neoplasm Staging/methods Reproducibility of Results Sensitivity and Specificity Urinary Bladder Neoplasms/*diagnostic imaging/*pathology

Adjuvants Immunologic/therapeutic use Administration Intravesical Consensus Humans Neoplasm Invasiveness Neoplasm Recurrence Local/drug therapy *Urinary Bladder Neoplasms/drug therapy Bladder neoplasms Expert consensus Intravesical therapy

Administration Intravesical BCG Vaccine/therapeutic use *Carcinoma in Situ/diagnosis/therapy Female Humans Male Neoplasm Invasiveness *Urinary Bladder Neoplasms/diagnosis/pathology/therapy *Urology *BCG unresponsive *Bacillus Calmette-Guerin (BCG) *Bladder cancer *Cystoscopy *Diagnosis *European Association of Urology (EAU) *Follow-up *Guidelines *Intravesical chemotherapy *Prognosis *Radical cystectomy *Transurethral resection (TUR) *Urothelial carcinoma

5-alpha Reductase Inhibitors/therapeutic use Androgen Antagonists/therapeutic use Androgens/therapeutic use *Carcinoma in Situ Humans Male *Prostatic Neoplasms/pathology *Urinary Bladder Neoplasms/pathology *Androgen suppression therapy *Androgens *Bladder cancer *Incidence *Recurrence *Systematic review

Antineoplastic Agents Alkylating/pharmacology/*therapeutic use Cyclophosphamide/pharmacology/*therapeutic use Female Humans Male Survival Analysis Urinary Bladder Neoplasms/*drug therapy/mortality Cyclophosphamide Hematuria Systematic review Urinary bladder neoplasms

Humans Incidence Risk Factors Suicide/*statistics & numerical data Urinary Bladder Neoplasms/diagnosis/*psychology Bladder cancer Meta-analysis Suicide Systematic review

Bayes Theorem Cystectomy Humans Laparoscopy Robotic Surgical Procedures Urinary Bladder Neoplasms/*surgery

Data Systems Humans *Multiparametric Magnetic Resonance Imaging Neoplasm Invasiveness Predictive Value of Tests Reproducibility of Results Urinary Bladder Neoplasms/*diagnostic imaging/pathology Bladder cancer Magnetic resonance imaging Meta-analysis Muscle invasive Systematic review Vesical Imaging Reporting and Data System

Cystectomy Humans Neoplasm Recurrence Local/surgery Prospective Studies *Urinary Bladder Neoplasms/surgery Urologic Surgical Procedures bladder cancer repeat restaging second look transurethral resection

Carcinoma Transitional Cell/secondary/*surgery Cystectomy/*adverse effects/methods Humans *Lymphatic Metastasis Neoplasm Recurrence Local/*epidemiology Peritoneal Neoplasms/epidemiology/*secondary Robotic Surgical Procedures/*adverse effects/methods Urinary Bladder Neoplasms/pathology/*surgery Atypical recurrence Bladder cancer Cystectomy Port-site metastases Rarc

Adjuvants Immunologic/adverse effects Administration Intravesical BCG Vaccine/adverse effects Humans *Urinary Bladder Neoplasms/drug therapy *Urology Antibiothérapie Antibiotic therapy BCG therapy BCG thérapie Bladder Carcinome urothélial Complications Endovesical instillations Instillations endovésicales Nmibc Tvnim Urothelial carcinoma Vessie

Adult Aged Aged 80 and over B7-H1 Antigen/genetics/*immunology Female Humans Immune Checkpoint Inhibitors/*administration & dosage *Immunotherapy Male Middle Aged Programmed Cell Death 1 Receptor/genetics/*immunology Progression-Free Survival Randomized Controlled Trials as Topic Treatment Outcome Urinary Bladder Neoplasms/genetics/immunology/mortality/*therapy efficacy immunotherapy meta-analysis safety urothelial cancer this study.

Guidelines as Topic Humans Immunotherapy/*methods Societies Medical/*standards Urinary Bladder Neoplasms/*drug therapy antineoplastic protocols immunotherapy urinary bladder neoplasms urologic neoplasms Pfizer AstraZeneca Nektar Seattle Genetics DragonFly Therapeutics Non-CME services: Genentech AstraZeneca Merck Seattle Genetics Contracted research: Genentech Merck AstraZeneca Nektar Seattle Genetics Immunomedics. PCB─Consulting fees: AbbVie Asieris Pharmaceuticals Astellas AstraZeneca Bayer Biosyent Bristol-Myers Squibb EMD Serono Ferring Fergene H3 Biomedicine Janssen Merck Roche Sanofi TerSera Urogen Contracted research: iProgen. MTC─Consulting fees: Pfizer EMD Serono AstraZeneca Exelixis Eisai Seattle Genetics Astellas Contracted research: Exelixis Pfizer/EMD Serono Janssen Apricity Health. GSD─Participant/unpaid volunteer: HealthVibe focus group 2020. MDG─Consulting fees: Inovio NuMab Janssen Merck GlaxoSmithKline Genentech Bristol-Myers Squibb Seattle Genetics Dracen Dragonfly Astellas Novartis Pfizer AstraZeneca Incyte Dendreon Eli Lilly EMD Serono Aileron Therapeutics Ownership interest: Rappta Therapeutics NPI: 1639140668. PG─Consulting fees: AstraZeneca Dyania Health EMD Serono Immunomedics Janssen Merck Mirati Therapeutics Genentech Pfizer Seattle Genetics Contracted Research: Bavarian Nordic Bristol-Myers Squibb Clovis Oncology Debiopharm Immunomedics Pfizer Merck QED Therapeutics GlaxoSmithKline Kure It Cancer Research Mirati Therapeutics. SG─Consulting fees: Merck Bristol-Myers Squibb Janssen Seattle Genetics AstraZeneca Contracted research: Bristol-Myers Squibb Pfizer Non-CME services: Exelixis. CJH─Consulting fees: Astellas Bristol-Myers Squibb Genentech Merck Eisai Seattle Genetics 2bPrecise Non-CME services: Astellas Bristol-Myers Squibb Genentech Eisai Seattle Genetics. AMK─Consulting fees: Abbott Molecular Arquer ArTara Asieris AstraZeneca BioClin Therapeutics Bristol-Myers Squibb Cepheid Cold Genesys Eisai Engene Inc. Ferring FerGene Imagin Janssen MDxHealth Medac Merck Pfizer Photocure ProTara Roviant Seattle Genetics Sessen Bio Theralase TMC Innovation US Biotest Contracted research: Adolor Bristol-Myers Squibb FKD Industries Heat Biologics Merck Photocure SWOG/NIH SPORE AIBCCR Clinical trials: FKD Merck Bristol-Myers Squibb Photocure SWOG Adolor Heat Biologics Laboratory research: NIH SPORE AIBCCR Educational grant: CEC Oncology Editorial board: European Urology Oncology Journal of Urology UroToday President of organization: International Bladder Cancer Network (IBCN) International Bladder Cancer Group (IBCG) IP Rights: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) Joint with UT MD Anderson Cancer Center. LPL─Consulting fees: Pfizer Advisory Nursing board 2018 Lecture/Speaker/Expert Panel: ASCO Bladder Program 2019 Pfizer learning day 2019 ASCO Bladder Program Panel Member and Faculty 2019 Pfizer Learning Day Speaker 2019 BCAN Webinar Faculty 11/2020. JJM─Consulting fees: AstraZeneca Ferring Janssen Nucleix Foundation Medicine Contracted research: Epizyme Tesaro Abbvie Teaching an endoscopy course: Olympus. ERP─Consulting fees: AstraZeneca Infinity Pharma Pfizer Flatiron Genentech Merck Seattle Genetics Contracted research: Astellas Bristol-Myers Squibb Genentech Merck. JER─Consulting fees: Merck Bristol-Myers Squibb AstraZeneca Astellas Seattle Genetics Boehringer Ingelheim Bayer Pfizer Roche/Genentech Mirati QED Therapeutics Janssen Pharmacyclics GlaxoSmithKline Contracted research/Clinical trial funding: Seattle Genetics Astellas Roche/Genentech Bayer AstraZeneca QED Therapeutics. NS─Consulting fees: Amgen Astellas AstraZeneca Bayer Bristol-Myers Squibb Dendreon Fergene Ferring Janssen Merck Myovant Nymox Pfizer Sanofi/Genzyme Sesen Bio Sun Pharma Tolmar. GDS─Consulting fees: Merck Janssen Ferring Bristol-Myers Squibb Pfizer Genentech Epivax Oncology AstraZeneca Fidia Cold Genesys EnGene Bio Aduro Biotech Dendreon FKD Therapies CiClomed Seattle Genetics Urogen PhotoCure. SITC staff: SMW—Shares owned: Pacific Biosciences Editas Medicine EG AK BL LL─Nothing to disclose.

Disease Progression Humans Muscle Smooth/pathology Neoplasm Grading Neoplasm Invasiveness Neoplasm Staging Treatment Failure Urinary Bladder/pathology Urinary Bladder Neoplasms/*pathology/*therapy *Watchful Waiting Active surveillance Non-Muscle Invasive bladder cancer Urothelial neoplasm

*Carcinoma Transitional Cell Evidence-Based Medicine Humans *Radiology Societies Medical United States *Urinary Bladder Neoplasms/diagnostic imaging Auc Appropriate Use Criteria Appropriateness Criteria Bladder cancer Muscle invasive bladder cancer Nonmuscle invasive bladder cancer Surveillance Transitional cell carcinoma Urothelial cancer

Carcinoma Transitional Cell/*mortality/pathology/surgery Cystectomy Disease-Free Survival Humans Neoplasm Recurrence Local/*diagnosis/epidemiology/pathology Prognosis Risk Assessment/methods Urinary Bladder/*pathology/surgery Urinary Bladder Neoplasms/*mortality/pathology/surgery Urothelium/*pathology/surgery histology meta-analysis urinary bladder neoplasms

Carcinoma Transitional Cell/epidemiology/*pathology Disease Progression Humans Neoplasm Invasiveness Neoplasm Recurrence Local/epidemiology Neoplasm Staging Prognosis Urinary Bladder Neoplasms/epidemiology/*pathology Bladder cancer Progression Staging Substage T1 Urothelial carcinoma pT1

Antineoplastic Agents/*therapeutic use Chemotherapy Adjuvant/*statistics & numerical data *Cystectomy Global Health Guideline Adherence/statistics & numerical data Humans Models Statistical Neoadjuvant Therapy/*statistics & numerical data Neoplasm Invasiveness Practice Guidelines as Topic Practice Patterns Physicians'/*statistics & numerical data Urinary Bladder Neoplasms/*drug therapy/pathology/surgery

Biomarkers Tumor/*urine DNA Neoplasm/*urine Humans RNA Neoplasm/*urine Urinary Bladder Neoplasms/*genetics/*urine Watchful Waiting Biomarkers Bladder Genetic Surveillance

Cystectomy/adverse effects/*methods Humans Laser Therapy/adverse effects/*methods Neoplasm Invasiveness Treatment Outcome Urethra Urinary Bladder Neoplasms/pathology/*surgery Bladder cancer Laser surgery Systematic review and meta-analysis Transurethral resection